How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
Journal of clinical oncology.
2017 Jul 10 ;
35 (20) :
2229-2231.
[epub] 20170504
Language English Country United States Media print-electronic
Document type Journal Article
Persistent link
https://www.medvik.cz/link/pmid28471725
- MeSH
- Time Factors MeSH
- Cetuximab adverse effects therapeutic use MeSH
- Squamous Cell Carcinoma of Head and Neck drug therapy mortality secondary virology MeSH
- Papillomavirus Infections virology MeSH
- Clinical Decision-Making MeSH
- Humans MeSH
- Neoplasm Recurrence, Local MeSH
- Head and Neck Neoplasms drug therapy mortality pathology virology MeSH
- Antineoplastic Agents, Immunological adverse effects therapeutic use MeSH
- Antineoplastic Combined Chemotherapy Protocols adverse effects therapeutic use MeSH
- Risk Factors MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Cetuximab MeSH
- Antineoplastic Agents, Immunological MeSH
References provided by Crossref.org
